Galipeau to replace Levine as ISCT president

May 11, 2022 -- Dr. Jacques Galipeau, associate dean for therapeutics development at the University of Wisconsin-Madison, is set to replace Bruce Levine, PhD, professor of cancer gene therapy at the University of Pennsylvania, as the next president (2022-2024) of the International Society for Cell & Gene Therapy (ISCT).

At the ISCT 2022 annual meeting in San Francisco, Galipeau, who is also director of the University of Wisconsin Advanced Cell Therapy Program, shared with his perspective on the opportunities for cell and gene therapies (CGTs).

When ISCT was founded 30 years ago, Galipeau pointed out that the field was "predicated on a lot of bone marrow transplant technology" but "what has really changed now is the advent of genetically armored or engineered cells, which really converts cells to pharmaceuticals in a way that goes far beyond simple transplantation of cells and tissue."

Galipeau describes the advancement as a "tectonic shift" as exemplified by the recent regulatory approvals of chimeric antigen receptor (CAR) T-cell therapies and interest from large pharma companies that "are now looking down on these as viable commercial products."

Watch the video below to learn more.

ISCT22: RoosterBio, ShiftBio partner to harness the power of MSCs, exosomes
RoosterBio, a supplier of human mesenchymal stem/stromal cells (MSCs), recently announced a strategic partnership with ShiftBio, a South Korean company...
ISCT22: Scale up of cell therapy manufacturing is a significant, but addressable challenge
The cell therapy industry is facing a significant but addressable challenge when it comes to scaling up manufacturing, according to Bob Newman, PhD, chief...
ISCT22: BroadOak’s Poltilove remains bullish on CGT market despite downturn
Bryan Poltilove, partner at BroadOak Capital Partners, spoke with at the International Society for Cell & Gene Therapy (ISCT)...
ISCT22: Orgenesis looks to simplify, lower costs of providing CGT therapies
Personalized cell and gene therapies (CGTs) offer the potential to address the most challenging diseases, Vered Caplan, CEO of biotech company Orgenesis,...
ISCT22: Children's National sees improved cell therapy potency, quicker patient delivery
Children's National Hospital in Washington, DC, is seeing improvements in the potency of existing cell therapies and a reduction in the time it takes...
ISCT22: Antion Biosciences CEO highlights new way of approaching allogeneic cell creation
Dr. Sven Kili, CEO of Antion Biosciences, contends the Swiss company’s microRNA (miRNA) technology (miCAR platform) is a new way of approaching allogeneic...
ISCT president calls for cell and gene therapy education, training amid ‘talent shortage’
This week in San Francisco, industry, investors, physicians, patients, and regulators convened at the International Society for Cell & Gene Therapy (ISCT)...
ISCT working group weighs in on expanded access to CGT
Patricia Zettler, JD, associate professor of law at The Ohio State University, and chair of the International Society for Cell & Gene Therapy (ISCT) Expanded...
ISCT22: Cell therapy has potential to address unmet medical needs in orthopedics
Miguel Forte, CEO of Bone Therapeutics, and president-elect of the International Society for Cell & Gene Therapy (ISCT), spoke with
ISCT22: Tackling the ethical issues around cell and gene therapy
Unproven and unethical cell and gene therapies are a growing problem worldwide, according to Laertis Ikonomou, PhD, of the Department of Oral Biology...

Copyright © 2022

Microscopy and Microanalysis Meeting
July 31 - August 4
Portland, Oregon United States
Glasgow International Health Festival
August 24-27
Glasgow, Glasgow City United Kingdom
Pharma Competitive Intelligence Conference and Exhibition
September 21-22
Newark, New Jersey United States
BioProcess International (BPI) Conference
September 27-30
Boston, Massachusetts United States
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter